Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2140 • 2014 ACR/ARHP Annual Meeting
Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis
Alexis Ogdie¹, Shiv Sehra², Viviane Khoury³, Yihui Jiang⁴, Shawn Rose⁵, Nehal N. Mehta⁶, Sally W. Pullman-Mooar⁷, Abass Alavi⁸, Joel Gelfand⁹ and Joshua Baker¹⁰, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Department of Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, ⁸Department of Radiology/Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA, ¹⁰Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose: The lack of tools to accurately measure and quantify joint inflammation is a challenging problem in the study of inflammatory arthritis. No gold standard…
Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Anna Cooper¹, Johan A. Karlsson² and Anders Gülfe¹, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…
Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saedis Saevarsdottir¹, Michele Santacatterina², Leszek Stawiarz³, Carl Turesson⁴, Helena Forsblad⁵, Lennart T.H. Jacobsson⁶ and Staffan Lindblad⁷, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
Abstract Number: 336 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 339 • 2013 ACR/ARHP Annual Meeting
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: The prevalence of obesity among patients with psoriatic arthritis (PsA) is increased compared to the general population. Obese patients with PsA tend to respond…
Abstract Number: 1462 • 2013 ACR/ARHP Annual Meeting
Unmasking The Tolerability Of Methotrexate In Patients With Rheumatoid and Psoriatic Arthritis: A Retrospective Review Of Discontinuation From a Large UK Cohort
Andra Negoescu¹, Elena Nikiphorou², Anshuman P. Malaviya³, Andrew Badcock³, John D. Fitzpatrick^3,4, Calum T. Goudie^3,4 and Andrew J. Ostor³, ¹Rheumatology, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Rheumatology, Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴University of Cambridge Medical School, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and perceived safety, methotrexate (MTX) has become the foundation disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA) however…
Abstract Number: 301 • 2013 ACR/ARHP Annual Meeting
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Odirlei Andre Monticielo¹, Karen Regina Rosso Schons², Cristiane Faccin Knob², Walter Neumaier², Maristela de Oliveira Beck² and André Avelino Costa Beber², ¹Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ²Universidade Federal de Santa Maria, Santa Maria, Brazil
Background/Purpose: Psoriasis is a chronic disease that presents in individuals of all ages, affecting skin, nails and joints. Nail changes are estimated to be present…
Abstract Number: 1367 • 2013 ACR/ARHP Annual Meeting
Performance Of a Two-Step Latent Tuberculosis Screening Algorithm In Patients With Rheumatoid Arthritis, Psoriatic Arthritis Or Ankylosing Spondylitis Prior To Treatment With Tumor Necrosis Alpha Inhibitors: Prospective Observational Data From The Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Reactivation of latent tuberculosis infection (LTBI) is of concern in patients treated with TNFi. Conversely, TB chemoprophylaxis (CP) is time consuming, delays the initiation…
Abstract Number: 310 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Arthur Kavanaugh², Dafna D. Gladman³, Adewale O. Adebajo⁴, Juan J. Gomez-Reino⁵, Jürgen Wollenhaupt⁶, Maurizio Cutolo⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²University of California San Diego, San Diego, CA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁵Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁶Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁷University of Genova, Genova, Italy, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy and safety of…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 311 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
Christopher J. Edwards¹, Francisco J. Blanco², Jeffrey Crowley³, ChiaChi Hu⁴, Randall M. Stevens⁴ and Charles A. Birbara⁵, ¹University of Southampton, Southampton, United Kingdom, ²INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Warren, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 3 compared the efficacy/safety of APR with placebo (PBO) in…
Abstract Number: 1291 • 2013 ACR/ARHP Annual Meeting
COVA322: Overcoming Limitations Of Current Biologics In Rheumatoid Arthritis By a Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor Moving Towards The Clinic
Dragan Grabulovski, Michela Silacci, Nadja Baenziger-Tobler, Wibke Lembke, Wenjuan Zha, Richard Woods, Isabella Attinger-Toller, Roger Santimaria, Susann Koenig-Friedrich, Ulrike von der Bey, Mathias Locher and Julian Bertschinger, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic treatment options such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there…
Abstract Number: 317 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Maurizio Cutolo¹, Philip J. Mease², Dafna D. Gladman³, Arthur Kavanaugh⁴, Adewale O. Adebajo⁵, Juan J. Gomez-Reino⁶, Jürgen Wollenhaupt⁷, Georg Schett⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹University of Genova, Genova, Italy, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California San Diego, San Diego, CA, ⁵Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁶Hospital Clinico Universitario, Santiago, Spain, ⁷Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
Abstract Number: 814 • 2013 ACR/ARHP Annual Meeting
Results Of a Randomised Controlled Trial Comparing Tight Control Of Early Psoriatic Arthritis (TICOPA) With Standard Care: Tight Control Improves Outcome
Laura C. Coates^1,2, Anna R. Moverley^1,2, Lucy McParland³, Sarah Brown³, Howard Collier³, Jennifer Law³, Sarah R. Brown³, Neil Corrigan³, Nuria Navarro-Coy^3,4, Paul Emery^2,5, Philip G. Conaghan^1,2 and Philip S. Helliwell^1,6, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: The aim of this study was to assess the impact of tight control of early psoriatic arthritis (PsA) in a randomised-controlled trial (RCT) using…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].